Evidence map›Paper›PMID 29329565›Full record

ArticleFluids and barriers of the CNS2018

Correction to: Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017.

John Greenwood, Margareta Hammarlund-Udenaes, Hazel C Jones, Alan W Stitt, Roosmarijn E Vandenbroucke, Ignacio A Romero, Matthew Campbell, Gert Fricker, Birger Brodin, Heiko Manninga and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Fluids and barriers of the CNS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

John GreenwoodInstitute of Ophthalmology, University College London, London, EC1V 9EL, UK.
Margareta Hammarlund-UdenaesDepartment of Pharmaceutical Biosciences, Uppsala University, 751 24, Uppsala, Sweden.
Hazel C JonesGagle Brook House, Chesterton, Bicester, OX26 1UF, UK. hazelcjones@btinternet.com.
Alan W StittCentre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
Roosmarijn E VandenbrouckeDepartment of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Ignacio A RomeroSchool of Life, Health and Chemical Sciences, Open University, Milton Keynes, UK.
Matthew CampbellSmurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland.
Gert FrickerInstitute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls University, Heidelberg, Germany.
Birger BrodinDepartment of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Heiko ManningaNEUWAY Pharma GmbH, Ludwig-Erhard-Allee 2, 53175, Bonn, Germany.
Pieter J Gaillard2-BBB Medicines BV, Leiden, Netherlands.
Markus SchwaningerInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.
Carl WebsterAntibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
Krzysztof B WicherOssianix Inc., Stevenage, UK.
Michel KhrestchatiskyCNRS, NICN, Aix Marseille Univ, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After publication of the article [1], it has been brought to our attention that there are some errors in the formatting of names in the final version of the article.

Identifiers

PMID29329565
PMCPMC5767039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.